ORPP logo

Curbside Consultation in Retina : (Record no. 5378)

MARC details
000 -LEADER
fixed length control field 07596nam a22004693i 4500
001 - CONTROL NUMBER
control field EBC5526246
003 - CONTROL NUMBER IDENTIFIER
control field MiAaPQ
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240724113359.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr cnu||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 240724s2018 xx o ||||0 eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781040140550
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN 9781630914509
035 ## - SYSTEM CONTROL NUMBER
System control number (MiAaPQ)EBC5526246
035 ## - SYSTEM CONTROL NUMBER
System control number (Au-PeEL)EBL5526246
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)1056072454
040 ## - CATALOGING SOURCE
Original cataloging agency MiAaPQ
Language of cataloging eng
Description conventions rda
-- pn
Transcribing agency MiAaPQ
Modifying agency MiAaPQ
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RE551 .C873 2019
082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 617.7/35
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Fekrat, Sharon.
245 10 - TITLE STATEMENT
Title Curbside Consultation in Retina :
Remainder of title 49 Clinical Questions.
250 ## - EDITION STATEMENT
Edition statement 2nd ed.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture Milton :
Name of producer, publisher, distributor, manufacturer Taylor & Francis Group,
Date of production, publication, distribution, manufacture, or copyright notice 2018.
264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice ©2018.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (298 pages)
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
490 1# - SERIES STATEMENT
Series statement Curbside Consultation in Ophthalmology Series
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Cover -- Half Page -- Title Page -- Copyright Page -- Dedication -- Table of Contents -- Acknowledgments -- About the Editor -- About the Associate Editors -- Contributing Authors -- Preface -- Foreword -- Introduction -- Question 1 What Is Hemorrhagic Occlusive Retinal Vasculitis, and Why Do I Need to Know About It? -- Question 2 How Do I Counsel My Patients With Dry Age-Related Macular Degeneration and What About Various Vitamin Supplements? -- Question 3 What Are the Age-Related Macular Degeneration Look-Alikes? Do I Treat Them Any Differently? -- Question 4 How Long Are We Going to Have to Keep Doing Frequent Intravitreal Injections Any Other Options Anytime Soon? What Are We Waiting For? -- Question 5 Anything Coming Down the Pike yet for Dry Age-Related Macular Degeneration? -- Question 6 Are We Ever Going to Use Stem Cells? For What? What's the Scoop? -- Question 7 What Is the Easiest Way to Do a Good B-Scan? -- Question 8 When Do I Refer a Patient With a Branch Retinal Artery Occlusion or Central Retinal Artery Occlusion, What Is the Work-Up, and What Are the Treatment Options? -- Question 9 What Do I Do When I See a Branch Retinal Vein Occlusion? -- Question 10 When Do I Refer a Patient With a Central Retinal Vein Occlusion, What Is the Work-Up, and What Are the Treatment Options? -- Question 11 What Visualization Agents Are Used During Vitrectomy Surgery? And Wait, Tell Me About the Intraocular Tamponade Options! -- Question 12 What Type of Intraocular Lens Should Be Considered in an Eye With Vitreoretinal Disease? -- Question 13 I Just Can't Keep Up With All of the Clinical Trial Acronyms. Can You Tell Me What Study Each Refers To? -- Question 14 How Do I Figure Out Whether or Not My Patient Has a Posterior Vitreous Detachment? Does There Have to Be a Weiss Ring to Make the Diagnosis?.
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note Question 15 How Soon Should a Patient With Floaters Be Examined and How Should I Manage a Patient With an Acute Posterior Vitreous Detachment? -- Question 16 How Do I Differentiate All of Those White Dot Syndromes? -- Question 17 How Do I Work Up and Manage a Patient With a White-Centered Retinal Hemorrhage? -- Question 18 How Do I Manage a Suprachoroidal Hemorrhage? -- Question 19 When Should I Suspect Endophthalmitis in My Postoperative Cataract Patient and What Are the Treatment Options? -- Question 20 How Do I Follow a Patient With a Presumed Choroidal Nevus? -- Question 21 How Do I Distinguish One Pigmented Lesion From Another? -- Question 22 How Do I Work Up and Manage a Patient With a Vitreous Hemorrhage? -- Question 23 What Is Fundus Autofluorescence? Do I Need to Add It to My Imaging Options? -- Question 24 What Additional Information Can I Get From Ultra-Widefield Fluorescein Angiography That I Can't Get From a 30-Degree Angiogram? -- Question 25 What Imaging Options Are There to Detect an Intraocular Foreign Body? When Do I Get Which One? -- Question 26 Why Would I Want to Look at Choroidal Thickness on Optical Coherence Tomography? -- Question 27 When Should I Refer a Patient With an Epiretinal Membrane and What if There Is Associated Cystoid Macular Edema? -- Question 28 How Do I Differentiate a Macular Hole From a Lamellar Hole From an Epiretinal Membrane With a Pseudohole, and Why Do I Care? -- Question 29 What Is Micropulse Laser and What Can It Be Used For? -- Question 30 What Is The Treatment Paradigm for Postoperative Pseudophakic Macular Edema? -- Question 31 What Is Dyeless Angiography (Optical Coherence Tomography Angiography) And What Do I Need To Know About It? Will It Replace Fluorescein Angiography? -- Question 32 Central Serous? What Now? Management Options for Central Serous Retinopathy.
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note Question 33 What Systemic Medications Require Periodic Fundus Evaluation? What Am I Looking for and What Tests Do I Do? -- Question 34 Should I Send a Patient With a Large Chronic Macular Hole to a Retina Doctor? Do They Even Operate on Those? -- Question 35 Explain All of These New Anticoagulants to Me. Should I Consider Stopping Them Preoperatively? -- Question 36 When Should Cataract Surgery Be Performed if a Vitrectomy Is Planned-Before, During, or After? -- Question 37 What Should I Tell a Patient With Retinitis Pigmentosa About Prognosis and Should I Prescribe Vitamin A or Other Supplements? -- Question 38 Why Should I Send My Retinal Degeneration Patients to Specialists if There Is No Cure for Their Condition? -- Question 39 What Is the Artificial Retinal Prosthesis (Argus II Implant) and Who Would Be a Good Candidate for It? -- Question 40 How Do You Differentiate Between Retinoschisis and Retinal Detachment? -- Question 41 What Systemic Conditions Are Associated With an Increased Risk of Retinal Detachment? What Should I Do About It? -- Question 42 What Retinal Findings Should Be Treated Before Cataract Surgery, Refractive Surgery, or Yttrium-Aluminum-Garnet Laser? -- Question 43 Do Chronic Rhegmatogenous Retinal Detachments Need Surgical Repair? -- Question 44 Should I Use Jetrea or a Gas Bubble or Just Do a Vitrectomy for Vitreomacular Traction? -- Question 45 When Should a Patient With Diabetic Retinopathy Be Considered for a Vitrectomy? -- Question 46 How Do I Follow a Patient Who Has Diabetes and Becomes Pregnant? What Tests Can I Do? -- Question 47 How Long Should I Wait to Perform Cataract Surgery After Treatment of Diabetic Macular Edema or Retinopathy? -- Question 48 I Saw Some Retinal Neovascularization but My Patient Does Not Have Diabetes, so What Else Can It Be?.
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note Question 49 When Should I Consider Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity? -- Financial Disclosures -- Index.
520 ## - SUMMARY, ETC.
Summary, etc. Curbside Consultation in Retina: 49 Clinical Questions, Second Edition contains new questions and brief, practical, and evidence-based answers to the most frequently asked questions that are posed during a "curbside consultation" between surgical colleagues.
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note Description based on publisher supplied metadata and other sources.
590 ## - LOCAL NOTE (RLIN)
Local note Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information Print version:
Main entry heading Fekrat, Sharon
Title Curbside Consultation in Retina
Place, publisher, and date of publication Milton : Taylor & Francis Group,c2018
International Standard Book Number 9781630914509
797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN)
Corporate name or jurisdiction name as entry element ProQuest (Firm)
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Curbside Consultation in Ophthalmology Series
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5526246">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5526246</a>
Public note Click to View

No items available.

© 2024 Resource Centre. All rights reserved.